Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718651 | 0.87 | NPC1 (0.77) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL10717636 | 0.87 | NPC1 (0.77) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL10717626 | 0.87 | NPC1 (0.77) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL20284039 | 0.82 | NPC1 (0.70) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL3713301 | 0.82 | NPC1 (0.70) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL19278568 | 0.82 | NPC1 (0.70) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL4135335 | 0.81 | NPC1 (1.00) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL17675351 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL11759969 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| SCHEMBL5645657 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3416633-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | The Board of Trustees of the University of Illinois (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| EP-2091538-A2 | 4-BENZYL-L(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | SMN1; SMN2 2423/4885NPC1 3355/4885RAB9A 3837/4885 |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC5, HDAC7 | SMN1; SMN2 609/4885NPC1 3278/4885RAB9A 1904/4885 |
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | SMN1; SMN2 4658/4885NPC1 39/4885RAB9A 1557/4885 |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | HDAC1, HDAC5, HDAC7 | SMN1; SMN2 609/4885NPC1 3278/4885RAB9A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.